Zobrazeno 1 - 10
of 31
pro vyhledávání: '"T. Likhacheva"'
Autor:
T.L. Kornishina, A.D. Kupreeva, M.M. Kostik, L.S. Snegireva, V. G. Chasnyk, A.A. Yakovlev, N.A. Gordeeva, A.G. Khabirova, A.V. Lobacheva, E. Isupova, M.F. Dubko, M.A. Kaneva, O. V. Kalashnikova, L. Sorokina, V. Masalova, T. Likhacheva, E.V. Gaidar, I.A. Chikova, K.E. Belozerov
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 100:143-153
TNF-α inhibitors are used in the treatment of non-systemic variants of juvenile idiopathic arthritis (JIA) in case of ineffectiveness or intolerance to methotrexate. Despite 20 years of experience of using of etanercept in pediatric rheumatology, a
Autor:
N.T. Garipova, I.A. Chikova, T. Likhacheva, V. Masalova, E.V. Gaidar, L. Sorokina, R.K. Raupov, E. Isupova, M.S. Asadulaev, A.Yu. Mushkin, M.M. Kostik
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 100:86-94
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, in which involvement of the cervical spine (CS) can lead to clinically significant and irreversible functional impairment. Objective of the study: to provide a com
Autor:
E.V. Gaidar, V.V. Masalova, Y.Y. Korin, M.F. Dubko, L.S. Sorokina, E.D. Orlova, L.S. Snegireva, I.A. Chikova, M.M. Kostik, T. Likhacheva, E. Isupova, Scientific, I.S. Avrusin
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 99:60-67
Autor:
I.А. Chikova, V.V. Masalova, N.T. Garipova, M.M. Gharabaghtsyan, E. Isupova, M.V. Rumyantseva, Consultative, T. Likhacheva, M.B. Paneyakh, S.R. Rodionovskaya, O.L. Krasnogorskaya, M.M. Kostik
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 99:125-136
Autor:
E. Kalashnikova, R. Raupov, N. Lybimova, E. Kuchinskaya, O. Kalashnikova, V. Chasnyk, T. Kornishina, L. Snegireva, E. Gaidar, V. Masalova, E. Isupova, M. Kaneva, M. Dubko, T. Likhacheva, L. Sorokina, M. Kostik
Publikováno v:
Annals of the Rheumatic Diseases. 81:997.2-997
Backgroundjuvenile systemic lupus erythematosus (jSLE) is the most frequent pediatric connective tissue disease with multiorgan involvement and different outcomes and prognosis. Corticosteroids remain the base treatment option and steroid-sparing tre
Publikováno v:
Proceedings of the Second Conference on Sustainable Development: Industrial Future of Territories (IFT 2021).
Autor:
V. Masalova, Lubov Sorokina, Ilia Avrusin, M. Kostik, T. Likhacheva, I.A. Chikova, M. Gharabaghtsyan, R. Raupov, E. Gaidar, L. Snegireva, S. Khrypov, M. Dubko, N. Garipova, E. Isupova
Publikováno v:
Annals of the Rheumatic Diseases. 80:931-932
Background:Hip osteoarthritis (HOA) is a severe outcome of juvenile idiopathic arthritis (JIA) itself and also can be result of corticosteroid (CS) treatment, if it was used. Total hip arthroplasty (THA) is the last step in JIA treatment and indicate
Autor:
I.A. Chikova, M. Dubko, M. Kostik, M. Kaneva, L. Snegireva, T. Likhacheva, T.L. Kornishina, E. Isupova, Vyacheslav Chasnyk, Olga Kalashnikova, V. Masalova, E. Gaidar
Publikováno v:
Annals of the Rheumatic Diseases. 80:937.1-937
Background:Macrophage activation syndrome (MAS) is a severe life-threatening complication of the systemic-onset juvenile idiopathic arthritis (soJIA). The treatment options included high-dose of the corticosteroids (CS), cyclosporine A (CsA), intrave
Autor:
M. Kostik, M. Kaneva, Olga Kalashnikova, M. Dubko, Vyacheslav Chasnyk, E. Isupova, V. Masalova, L. Snegireva, I.A. Chikova, T. Likhacheva, E. Gaidar, M. Chakhalian, T. Nikitina
Publikováno v:
Annals of the Rheumatic Diseases. 80:1402.2-1402
Background:Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). Usually uveitis developed during first two years after arthritis occurred [1]. In the previous studies was shown the shorter time interval bet
Autor:
R. Raupov, V. Masalova, Evgeny N. Suspitsin, Vyacheslav Chasnyk, Lubov Sorokina, T. Ermachenkova, T. Likhacheva, M. Kostik, Olga Kalashnikova, T. Gabrusskaya, E. Gaidar, M. Dubko, L. Snegireva, E. Isupova, M. Kaneva
Publikováno v:
Annals of the Rheumatic Diseases. 80:247.1-248
Background:While efficacy of tofacitinib (TOF) has been proven in many adult immune-mediated conditions, the information on its’ safety and efficacy in the pediatric population is limited.Objectives:to evaluate the safety and efficacy of TOF in chi